Anna D. Kosinska
Munich, BY 81675, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications
Long-term antigen reduction does not achieve durable HBV control in mice but enhances therapeutic vaccine efficacy.
Journal: JHEP reports : innovation in hepatology
Published: March 21, 2026
Protein Priming Followed by a Replication-Competent VSV-GP Vector Boost Induces Sustained Immune Control in Therapeutic Hepatitis B Vaccination.
Journal: Vaccines
Published: January 04, 2026
Therapeutic hepatitis B vaccine employing DNA prime - MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response.
Journal: Frontiers in immunology
Published: December 19, 2025
HERV-K10 as a mediator of immune modulation in hepatitis infections.
Journal: Frontiers in immunology
Published: May 07, 2025
MVA-HBVac-A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination.
Journal: Molecular therapy. Nucleic acids
Published: February 04, 2025
Investigation of Erosion and Deposition Due to Flows with Particles.
Journal: Langmuir : the ACS journal of surfaces and colloids
Published: November 14, 2024
Production and Purification of Adeno-Associated Viral Vectors for the Development of Immune-Competent Mouse Models of Persistent Hepatitis B Virus Replication.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: July 23, 2024
The lack of HBsAg secretion does neither facilitate induction of antiviral T cell responses nor Hepatitis B Virus clearance in mice.
Journal: Antiviral research
Published: January 31, 2024
CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells.
Journal: Frontiers in immunology
Published: November 18, 2023
Exploring the use of nanofluids in pump-free systems for solar thermal applications.
Journal: Scientific reports
Published: July 31, 2023
Introducing adjuvant-loaded particulate hepatitis B core antigen as an alternative therapeutic hepatitis B vaccine component.
Journal: JHEP reports : innovation in hepatology
Published: May 11, 2023
Last Updated: 09/26/2026